Anzeige
Mehr »
Lynx Broker
Login
Mittwoch, 16.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien
Konkurrenz beeindruckt! Bisher noch unentdeckt von Investoren ist die neue Technologie jetzt marktreif! Aktie vor Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14SVV ISIN: FR0012596468 Ticker-Symbol: RFM 
Stuttgart
16.10.19
13:14 Uhr
1,016 Euro
-0,018
-1,74 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SENSORION SA Chart 1 Jahr
5-Tage-Chart
SENSORION SA 5-Tage-Chart

Aktuelle News zur SENSORION Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.09.Sensorion completes a capital increase of €18.1 million subscribed by leading biotech investors358The capital increase will solidify Sensorion's financial position, following the €20m raise from June 2019, subscribed by Invus Public Equities LP and Sofinnova Crossover I SLP The additional...
► Artikel lesen
17.09.Sensorion Announces Two Presentations at AAO-HNSF 2019 in New Orleans205Clinical data demonstrating lack of sedation or cognitive impairment by SENS-111 (Seliforant) Preclinical data on circulating prestin levels in a model of mild noise-induced hearing loss Regulatory...
► Artikel lesen
11.09.Sensorion Announces Three Presentations at IEB 2019 in Padua142An oral presentation in the session "Beyond the Device: New Therapeutic Approaches for Hearing Loss" on SENS-401 Two preclinical posters on ototoxicity Regulatory News: Sensorion...
► Artikel lesen
Börsennews zur SENSORION Aktie und weiteren Hot Stocks erhalten
07.08.Sensorion Announces Appointment of John Furey, Former COO of Spark Therapeutics, as Independent Board Member57Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent...
► Artikel lesen
31.07.Sensorion: Reporting of the General Assembly Appointment of Three New Directors32Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biopharmaceutical company which specialises in the development of novel therapies to restore, treat and prevent inner ear diseases such as...
► Artikel lesen
15.07.Sensorion receives FDA IND approval for Arazasetron1
12.07.Sensorion Receives FDA IND Approval for Arazasetron (SENS-401)47Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat...
► Artikel lesen
01.07.Sensorion receives EMA agreement on the pediatric investigation plan for Arazasetron in two indications-
01.07.Sensorion Announces an Oral Presentation at the 5th Congress of European ORL-Head & Neck Surgery in Brussels31Participation in the round table session named "Novel hearing therapeutics; what does it mean for the ENT surgeon?" Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage...
► Artikel lesen
28.06.Sensorion Receives European Medicines Agency Agreement on the Pediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in Two Indications31This agreement paves the way for the submission of a marketing authorization application in Europe Regulatory News: Sensorion (Paris:ALSEN)(FR0012596468 ALSEN) a pioneering clinical-stage...
► Artikel lesen
26.06.Sensorion Announces That the "AUDINNOVE" Project of Which Sensorion Is a Partner Is a Laureate of the Fourth Solicitation Request for Funding From RHU as Part of the French "Avenir Investment Program"39The "AUDINNOVE" project led by AP-HP in partnership with Institut Pasteur, "la Fondation pour l'Audition" and Sensorion will receive a 9.7m grant funding Involves one of the two gene therapy...
► Artikel lesen
12.06.Sensorion Announces a €20m Convertible Bond Issue Subscribed by Two Renowned Investors Invus and Sofinnova Partners65€20m issue of bonds mandatorily convertible into ordinary shares of the Company subscribed by Invus Public Equities LP and Sofinnova Crossover I SLP, which become long-term partners...
► Artikel lesen
03.06.Sensorion Announces Poster Presentation at the "Société Internationale d'Otoneurologie" Symposium35Presentation of SENS-111 phase 2 study protocol in Acute Unilateral Vestibulopathy (AUV) Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ALSEN) a pioneering clinical-stage...
► Artikel lesen
29.05.Sensorion: Reporting of the General Assembly33Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ALSEN) a pioneering clinical-stage biopharmaceutical company which specialises in the development of novel therapies to restore...
► Artikel lesen
27.05.Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss40This agreement defines an exclusive option to obtain licences for joint programs including Otoferlin Usher Type 1 and preference rights on the research pipeline in the field of genetic disorders...
► Artikel lesen
17.05.Sensorion announces oral presentation at the European Histamine Research Society23Presentation of an overview of SENS-111 development Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in...
► Artikel lesen
15.05.Sensorion Announces the Positive Data Safety Monitoring Board (DSMB) Review and Continuation of the Phase 2 Clinical Trial for SENS-111 in Acute Unilateral Vestibulopathy (AUV)2686 patients enrolled in SENS-111 clinical trial Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes...
► Artikel lesen
13.05.Sensorion's 2018 Financial Report is Now Available46Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore...
► Artikel lesen
27.03.Sensorion Reports Its 2018 Annual Results; 75% of Patients Enrolled in the Sens-111 Clinical Trial28SENS-111 phase 2 AUV trial: major progress with 75% of patients enrolled in the clinical trial assessing the efficacy of SENS-111 on vertigo intensity SENS-111 phase 2a trial:...
► Artikel lesen
11.03.Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management23Bpifrance has selected Sensorion for its program "Hub Health Tech" Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ALSEN), a pioneering clinical-stage biopharmaceutical...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1